LIDDS has entered into a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. The scope of the program is to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The agreement includes clearly defined research stages and an exclusive opportunity to negotiate a complete license agreement. In January 2022, LIDDS announced that stage 1 of the collaboration had been completed and the Joint Research Committee agreed to move the project to stage 2 of the feasibility program.